Home » Stocks » GALT

Galectin Therapeutics Inc. (GALT)

Stock Price: $3.82 USD -0.18 (-4.50%)
Updated May 10, 2021 3:29 PM EDT - Market open
Market Cap 228.62M
Revenue (ttm) n/a
Net Income (ttm) -23.60M
Shares Out 57.03M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $3.82
Previous Close $4.00
Change ($) -0.18
Change (%) -4.50%
Day's Open 3.94
Day's Range 3.75 - 4.04
Day's Volume 391,542
52-Week Range 1.82 - 5.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D.,...

1 week ago - GlobeNewsWire

Galectin Therapeutics Inc (NASDAQ: GALT) has announced that a paper in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC) published data from an ongoing Phase 1 trial evaluating Galectin's bel...

3 weeks ago - Benzinga

Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) alone Combination therapy with belapectin suggests a better objecti...

3 weeks ago - GlobeNewsWire

Galectin Therapeutics is actively recruiting patients into NAVIGATE, its seamless, adaptive Phase 2b/3 study of belapectin for the prevention of esophageal varices in NASH cirrhosis Galectin Therapeutic...

1 month ago - GlobeNewsWire

NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and pro...

1 month ago - GlobeNewsWire

NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., ...

4 months ago - GlobeNewsWire

Chairman Dick Uihlein, CEO and President Joel Lewis, and Chief Medical Officer Pol Boudes Provide Corporate Highlights on Company's Three Active Clinical Trials Chairman Dick Uihlein, CEO and President ...

5 months ago - GlobeNewsWire

Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated

6 months ago - GlobeNewsWire

Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel Lewis Presentation to discuss the details of the newly launched Phase 2b...

7 months ago - GlobeNewsWire

Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel Lewis Presentation to discuss the details of the newly launched Phase 2b...

7 months ago - GlobeNewsWire

NORCROSS, Ga., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management wil...

8 months ago - GlobeNewsWire

Dr. Harold Shlevin retires as CEO, transitions to role of scientific and business consultant and will remain on the Board

8 months ago - GlobeNewsWire

NASH-RX Trial Continues to Enroll New Patients NASH-RX Trial Continues to Enroll New Patients

9 months ago - GlobeNewsWire

Intercept's Pain Is Galectin's Gain: Clinical Outcomes In NASH Are Crucial

10 months ago - Seeking Alpha

Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy

10 months ago - GlobeNewsWire

Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy

10 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Galectin Therapeutics.

11 months ago - Zacks Investment Research

NASH-RX Clinical Trial Protocol Filed with FDA; First Patient Currently Expected to be Enrolled in Second Quarter 2020

11 months ago - GlobeNewsWire

The first patient currently expected to be enrolled in the second quarter of 2020 The first patient currently expected to be enrolled in the second quarter of 2020

1 year ago - GlobeNewsWire

Finding The Kink In COVID-19's Armor - Preventing ARDS

Other stocks mentioned: AMPE, CYDY, GILD, RHHBY
1 year ago - Seeking Alpha

NORCROSS, Ga., April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact...

1 year ago - GlobeNewsWire

Galectin Therapeutics: An Even Better Buy As It Hits 52-Week Lows

1 year ago - Seeking Alpha

Interim analysis after 12-18 months of treatment to reaffirm phase 2 results, select optimal dosage and sizing and seamlessly roll into Phase 3 stage of NASH-RX Study

1 year ago - GlobeNewsWire

Small Drug Stock Outlook: Innovation Holds the Key to Growth

Other stocks mentioned: LCI, VRCA, ZTS
1 year ago - Zacks Investment Research

I provide a basic overview of Galectin Therapeutics, and where it, and galectin-3 research, stands today.

Other stocks mentioned: MRK
2 years ago - Seeking Alpha

Since Galectin announced funding plans for the Phase 3 trial via a rights offering, most investors have waited "patiently" for updates on the clinical and financial plans.

2 years ago - Seeking Alpha

Recent third-party research bodes well for GALT's GR-MD-02.

2 years ago - Seeking Alpha

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which i... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
Harold Shlevin
Employees
6
Stock Exchange
NASDAQ
Ticker Symbol
GALT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for GALT stock is "Buy" and the 12-month stock price forecast is 14.00.

Price Target
$14.00
Analyst Consensus: Buy